Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057.

2.

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.

Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP.

Semin Oncol. 2003 Jun;30(3 Suppl 6):32-8. Review.

PMID:
12802793
3.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
4.
5.

Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.

Underiner TL, Ruggeri B, Gingrich DE.

Curr Med Chem. 2004 Mar;11(6):731-45. Review.

PMID:
15032727
6.
7.

Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.

Pradeep CR, Sunila ES, Kuttan G.

Integr Cancer Ther. 2005 Dec;4(4):315-21. Review.

PMID:
16282508
8.

Vascular endothelial growth factor and its inhibitors.

Verheul HM, Pinedo HM.

Drugs Today (Barc). 2003;39 Suppl C:81-93. Review.

PMID:
14988747
9.

Antiangiogenic agents: an update on small molecule VEGFR inhibitors.

Schenone S, Bondavalli F, Botta M.

Curr Med Chem. 2007;14(23):2495-516. Review.

PMID:
17979703
10.

Vascular endothelial growth factor (VEGF) inhibition--a critical review.

Moreira IS, Fernandes PA, Ramos MJ.

Anticancer Agents Med Chem. 2007 Mar;7(2):223-45. Review.

PMID:
17348829
11.

VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.

Sharma PS, Sharma R, Tyagi T.

Curr Cancer Drug Targets. 2011 Jun;11(5):624-53. Review.

PMID:
21486218
12.

PTK/ZK (Novartis).

Drevs J.

IDrugs. 2003 Aug;6(8):787-94. Review.

PMID:
12917775
13.

Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature.

Backer MV, Hamby CV, Backer JM.

Adv Genet. 2009;67:1-27. doi: 10.1016/S0065-2660(09)67001-2. Review.

PMID:
19914448
14.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
15.

The applicability of mTOR inhibition in solid tumors.

Konings IR, Verweij J, Wiemer EA, Sleijfer S.

Curr Cancer Drug Targets. 2009 May;9(3):439-50. Review.

PMID:
19442061
16.

Vascular endothelial growth factor receptors: expression and function in solid tumors.

Wey JS, Stoeltzing O, Ellis LM.

Clin Adv Hematol Oncol. 2004 Jan;2(1):37-45. Review.

PMID:
16163158
17.
18.

Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.

Agarwala SS, Case S.

Oncologist. 2010;15(3):236-45. doi: 10.1634/theoncologist.2009-0141. Review.

19.

[Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].

Shuuin T, Karashima H.

Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. Review. Japanese.

PMID:
19620795
20.

Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.

Zhang C, Tan C, Ding H, Xin T, Jiang Y.

Curr Pharm Des. 2012;18(20):2921-35. Review.

PMID:
22571661
Items per page

Supplemental Content

Support Center